Physician profile
John E Castro
NPI 1508815275
$9,855.65
in general payments reported to CMS, 2019-2025
9 companies · $4,583 in 2025
The $4,583 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $65.87 · 2021: $443 · 2022: $1,391 · 2023: $974 · 2024: $1,689 · 2025: $4,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,281 · Honoraria: $2,500 · Entertainment: $447 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,280.70 |
| Honoraria | $2,500.00 |
| Entertainment | $447.04 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $2,981.12 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $2,738.61 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Bausch & Lomb Americas INC. | $1,334.46 | 2022-2025 | Miebo, Xiidra, Infuse |
| Johnson & Johnson Vision Care, INC. | $1,311.36 | 2019-2025 | Acuvue |
| Coopervision INC. | $650.61 | 2022-2025 | Clariti Contact Lens, Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $352.50 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $262.81 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $148.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $75.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.